J Agromedicine:美国农场经营者农药的使用、过敏性鼻炎和哮喘情况分析

2018-09-23 AlexYang MedSci原创

最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘之间的相关性。研究人员分析了2011年11210名主要农场经营者的农场和牧场安全调查数据。农药的使用通过调查问卷的方式来进行确定,即询问在调查前的12个月内是否混合、装载或者使用农药。那些回答肯定的参与者进一步询问商品的名称和产品的制定标识符以及个人的防护设备(PPE)情况。研究人员对数据进行了加权从而对全国的情况进行评估,

最近,有研究人员在美国农场经营者中调查了特殊农药的使用与过敏性鼻炎以及哮喘之间的相关性。

研究人员分析了2011年11210名主要农场经营者的农场和牧场安全调查数据。农药的使用通过调查问卷的方式来进行确定,即询问在调查前的12个月内是否混合、装载或者使用农药。那些回答肯定的参与者进一步询问商品的名称和产品的制定标识符以及个人的防护设备(PPE)情况。研究人员对数据进行了加权从而对全国的情况进行评估,并利用逻辑回归对调整后的风险比(PORs)进行了推算。对照组包括了那些没有使用农药的经营者。研究发现,在评估了210万农场经营者中。40%使用了农药,30.8%具有过敏性鼻炎。5.1%具有哮喘。杀虫剂和除草剂与过敏性鼻炎和哮喘显著相关。 2,4-二氯苯氧乙酸(POR = 1.5; 95% CI 1.2-1.9)和胺甲萘(POR = 2.3; 1.4-3.7)的使用与过敏性鼻炎显著相关。在那些使用农药的经营者中,64.9%的参与者使用了PPE。

最后,研究人员指出,在农场经营者中,农药与过敏性鼻炎和哮喘相关。进一步的研究需要去鉴定剂量响应在农药使用和健康副作用之间的关系。

原始出处:

Patel O, Syamlal G, Henneberger PK et al. Pesticide use, allergic rhinitis, and asthma among US farm operators. J Agromedicine. 2018

本文系梅斯医学(MedSci)原创编译和整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2019-06-13 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2019-07-07 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2019-02-15 Homburg
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1858898, encodeId=4fcf185889844, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Thu Jun 13 20:29:00 CST 2019, time=2019-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773731, encodeId=6d5b1e7373150, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Sun Jul 07 13:29:00 CST 2019, time=2019-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047024, encodeId=ff21204e0242c, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 30 07:29:00 CST 2019, time=2019-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704227, encodeId=d1e91e04227a9, content=<a href='/topic/show?id=afc1308021a' target=_blank style='color:#2F92EE;'>#农药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30802, encryptionId=afc1308021a, topicName=农药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=200530724401, createdName=Homburg, createdTime=Fri Feb 15 12:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577623, encodeId=eac815e7623c1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609128, encodeId=9ad51609128bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Sep 25 01:29:00 CST 2018, time=2018-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346420, encodeId=ded23464209f, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Mon Sep 24 10:38:09 CST 2018, time=2018-09-24, status=1, ipAttribution=)]
    2018-09-24 ylzr123

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

相关资讯

Int J Ophthalmol:季节过敏性结膜炎风险因子调查

最近,有研究人员通过皮肤过敏测试和调查问卷中获得的数据,分析了发展为季节过敏性结膜炎(SAC)可能的风险因素。研究包括了75名SAC患者和71未诊断为SAC的对照。调查的时间为2016年3月到2016年12月之间。研究人员对所有的参与者进行了皮刺试验,并测量了血清总lgE和25-OH维他命D的水平。研究人员同时也调查了SAC发生的可能风险因素,比如抽烟、对乙酰氨基酚接触、维生素D补充和环境因素等。

Asian Pac J Allergy Immunol:有氧训练和维生素C补充对过敏性鼻炎患者鼻炎症状的影响研究

运动锻炼和维生素C补充在许多疾病的症状治疗中均推荐作为一种有效的辅助治疗方法。然而,它们对鼻炎症状的影响仍旧不清楚。最近,有研究人员评估了单独的有氧训练和有氧训练结合维生素C补充对分别对过敏性鼻炎患者症状的影响。研究包括了27名鼻炎患者,并被随机分配到3个小组:对照组(CON;n=8),训练组(EX;n=9)和锻炼与维生素C结合组(EX+Vit.C;n=10)。锻炼的方法包括走路和或者跑步。维生素

盘点:鼻炎研究进展

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Med Sci Monit:辅助性T9细胞的激活与过敏

Curr Med Res Opin:一个大群体的舌下免疫治疗花费研究

在美国人口中,过敏性鼻炎(AR)影响的人数占比了高达40%,每年的医疗花费大约110亿美元。过敏免疫治疗是长期症状缓解的最好的选择,但是治疗依从性低。最近,有研究人员调查了那些接受全部免疫治疗和那些免疫治疗间断患者的舌下免疫治疗(SCIT)相关的花费情况。研究发现,与对照(n=394479)相比,SCIT(n=131493)患者更加年轻(39.3 vs. 41.4 ),并且女性占比较高(56.4%

Respir Med:嗜伊红细胞性肉芽肿病且伴随多血管炎的过敏性患者中重度/不受控制哮喘和总生存研究

尽管哮喘、鼻炎/鼻窦炎和外周嗜酸性粒细胞事实上在所有嗜伊红细胞性肉芽肿病且伴随多血管炎(EGPA)的患者中存在,而特异性反应在这些患者中却没有很好的研究。最近,有研究人员鉴定了特异性反应对患有EGPA患者的影响。研究发现,总体来讲,33.5%(63)的患者经历了针对气源性致敏原的皮肤和/或特异性lgE测试。与气源性致敏原相关的特异性反应在22.3%的患者(占进行测试的2/3)中鉴定到,并且特异性反

PLoS One:在鼻腔分泌物中利用广泛的生物标记对非过敏性鼻炎、过敏性和混合型鼻炎患者分型研究

慢性鼻炎的分型对非过敏性鼻炎(NAR)患者来说是最困难的。虽然过敏性鼻炎(AR)典型的症状时lgE相关的炎症,然而,目前还没有发现能够鉴定NAR的阳性标记。一个更加复杂的问题是AR和NAR在混合型鼻炎患者中可能是共存的。最近,有研究人员利用分子或者细胞标记物对慢性鼻炎和非过敏性鼻炎进行了分型研究。研究包括了23名NAR患者,并且没有敏感过敏原且患有永久性鼻炎症状;22名花粉敏感鼻炎患者伴随季节性症